Radiotherapy-free neoadjuvant strategy using sintilimab plus XELOX in locally advanced rectal cancer: A single-arm phase II trial

Table 3 Adverse events during neoadjuvant therapy, n (%)

Treatment-related adverse events	Grade I-II	≥ grade III	All grade
Hematology related
WBC reduction	7 (17.1)	0 (0)	7 (17.1)
Anemia	5 (12.2)	0 (0)	5 (12.2)
PLT reduction	0 (0)	0 (0)	0 (0)
ALT increase	9 (22.0)	0 (0)	9 (22.0)
AST increase	9 (22.0)	0 (0)	9 (22.0)
Elevated bilirubin	3 (7.3)	0 (0)	3 (7.3)
Renal failure	2 (4.9)	0 (0)	2 (4.8)
Total	21 (51.2)	0 (0)	21 (51.2)
Non hematology
Weak	1 (2.4)	0 (0)	1 (2.4)
Nausea	1 (2.4)	0 (0)	1 (2.4)
Diarrhea	9 (22.0)	0 (0)	9 (22.0)
Constipation	1 (2.4)	0 (0)	1 (2.4)
Rash	2 (4.8)	0 (0)	2 (4.8)
Abdominal pain	0 (0)	0 (0)	0 (0)
Hypothyroidism	1 (2.4)	1 (2.4)	2 (4.8)
Hyperthyroidism	0 (0)	0 (0)	0 (0)
Lumbago	0 (0)	0 (0)	0 (0)
Total	15 (36.6)	1 (2.4)	16 (39.0)

WBC: White blood cell; PLT: Platelets; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.